Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
triazole antifungal |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2015 |
| gptkbp:ATCCode |
J02AC11
|
| gptkbp:brand |
gptkb:Cresemba
|
| gptkbp:CASNumber |
241479-67-4
|
| gptkbp:developedBy |
gptkb:Astellas_Pharma
gptkb:Basilea_Pharmaceutica |
| gptkbp:eliminationHalfLife |
130 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C22H17F2N5O
|
| https://www.w3.org/2000/01/rdf-schema#label |
isavuconazole
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits fungal cytochrome P450 enzyme 14α-demethylase
|
| gptkbp:metabolism |
liver (CYP3A4, CYP3A5)
|
| gptkbp:molecularWeight |
437.4 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prodrugOf |
isavuconazonium sulfate
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea elevated liver enzymes hypokalemia |
| gptkbp:usedFor |
gptkb:mucormycosis
gptkb:invasive_aspergillosis |
| gptkbp:bfsParent |
gptkb:J02AC
gptkb:mucormycosis gptkb:invasive_aspergillosis gptkb:Cresemba |
| gptkbp:bfsLayer |
7
|